2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-142683
    SCP1-IN-2 2764615-56-5 98.77%
    SCP1-IN-2 (Compound SH T-65) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-2 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-2 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity.
    SCP1-IN-2
  • HY-142868
    ONO-8713 459411-08-6 99.0%
    ONO-8713 is a selective prostaglandin E receptor subtype EP1 antagonist.
    ONO-8713
  • HY-143316
    NPR-C activator 1 2768328-61-4 99.30%
    NPR-C activator 1 (Compound 1) is a potent activator of natriuretic peptide receptor C (NPR-C). C-type natriuretic peptide (CNP) is involved in the regulation of vascular homeostasis. NPR-C activator 1 is identified as a potent agonist (EC50 ∼ 1 μM) with promising in vivo pharmacokinetic properties.
    NPR-C activator 1
  • HY-144270
    Glucosylceramide synthase-IN-3 3029827-91-3 99.11%
    Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-3
  • HY-144377
    RXR antagonist 1 3010910-40-1 99.94%
    RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research.
    RXR antagonist 1
  • HY-144604
    FPR2 agonist 2 2829263-20-7 98.51%
    FPR2 agonist 2 is a potent and CNS-penetrant FPR2 agonist with an EC50 of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity.
    FPR2 agonist 2
  • HY-14536R
    Methylene Blue (Standard) 61-73-4
    Methylene Blue (Standard) is the analytical standard of Methylene Blue. This product is intended for research and analytical applications. Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
    Methylene Blue (Standard)
  • HY-14546A
    Aripiprazole monohydrate 851220-85-4 99.83%
    Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19.
    Aripiprazole monohydrate
  • HY-14566A
    (S)-Donepezil 142057-80-5 99.82%
    (S)-Donepezil is a S-enantiomer of Donepezil (HY-14566). Donepezil is a specific and potent AChE inhibitor.
    (S)-Donepezil
  • HY-145830
    AC1-IN-1 2762422-55-7 99.32%
    AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 μM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain.
    AC1-IN-1
  • HY-147108
    Mitochondria degrader-1 2241669-05-4
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease.
    Mitochondria degrader-1
  • HY-147132
    GluR6 antagonist-1 323176-64-3 98.0%
    GluR6 antagonist-1 is a benzothiophene derivative, acting as a GluR6 antagonist. GluR6 antagonist-1 can be used for researching acute and chronic neurological disorders.
    GluR6 antagonist-1
  • HY-147134
    GSK-3β inhibitor 10 1198098-03-1 98.04%
    GSK-3β inhibitor 10 (compound 14a) is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease.
    GSK-3β inhibitor 10
  • HY-147545
    A1AR antagonist 6 329693-22-3 98.13%
    A1AR antagonist 6 (compound 15) is a potent and selective A1AR (A1 adenosine receptor) antagonist, with a pIC50 of 6.38 and a pKi of 7.13.
    A1AR antagonist 6
  • HY-147976
    Glucocerebrosidase-IN-1 2279945-76-3 99.65%
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD).
    Glucocerebrosidase-IN-1
  • HY-148114
    MOPIPP 1485521-76-3 98.54%
    MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-119624). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP can be used for the study of glioblastoma cells.
    MOPIPP
  • HY-148165
    L-Cytidine 26524-60-7 99.98%
    L-Cytidine is an L-configurational form of Cytidine (HY-B0158). L-Cytidine is a pyrimidine nucleoside, a component of RNA. Cytidine can control the glial glutamate cycle, affect brain phospholipid metabolism, catecholamine synthesis and mitochondrial function.
    L-Cytidine
  • HY-148455
    Casein kinase 1δ-IN-3 349438-77-3 99.50%
    Casein kinase 1δ-IN-3 (Compound 23a) is a casein kinase 1 delta (CK1d) inhibitor with a pIC50 of 6.5376 M.
    Casein kinase 1δ-IN-3
  • HY-148492
    Mrgx2 antagonist-2 2767111-67-9 98%
    Mrgx2 antagonist-2 (Example 132) is a Mrgx2 antagonist with a pIC50 of 8.6. Mrgx2 antagonist-2 can be used in the research of MrgX2 -mediated diseases or disorders.
    Mrgx2 antagonist-2
  • HY-149054
    GSK-3β inhibitor 13 2227316-74-5 99.74%
    GSK-3β inhibitor 13 (compound 47) is an orally active and potent GSK-3β inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits GSK-3β and GSK-3α with IC50s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC50=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease.
    GSK-3β inhibitor 13
Cat. No. Product Name / Synonyms Application Reactivity